Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Teva Pharmaceutical Industries Limited ("Teva" or the "Company") (NYSE: TEVA). Investors who purchased or otherwise acquired shares between February 10, 2015 and November 3, 2016 inclusive (the "Class Period"), are encouraged to contact the Firm prior to the January 5, 2017 lead plaintiff motion deadline. If you purchased Teva shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org. There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member. The complaint alleges that Teva made false and/or misleading statements and/or failed to disclose that: Teva engaged in conduct that would result in a Department of Justice ("DOJ") antitrust investigation; that the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against the Company by the end of 2016 for suspected price collusion; that Teva lacked effective internal controls; and that as a result of the above, the Company's public statements were materially false and misleading at all relevant times. On November 3, 2016, Bloomberg News reported that the Justice Department is conducting an antitrust investigation of over a dozen companies, including Teva, to determine whether they unlawfully colluded with each other to fix generic drug prices. When this information was disclosed to the public, shares of Teva dropped in value. If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at email@example.com. This press release may constitute Attorney Advertising in some jurisdictions.